Electron spin resonance spectroscopy of serum albumin: A novel new test for cancer diagnosis and monitoring

Steven (Steve) Kazmierczak, Andrey Gurachevsky, Gert Matthes, Vladimir Muravsky

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: Proteins released by tumor cells can bind to serum albumin, leading to structural and functional modifications. We used electron spin resonance (ESR) spectroscopy to measure these changes in serum albumin and evaluate their utility for the diagnosis and monitoring of cancer. Methods: We used an ESR spectrometer and 16-doxyl stearic acid as spin probe to measure conformational changes in albumin in blood samples from a population of healthy donors and volunteers (n = 349), patients with a wide variety of hematologic and nonhematologic malignancy (n = 135), and patients with chronic diseases such as gastrointestinal and pulmonary disease, diabetes, and cirrhosis (n = 91). We added differing amounts of 16-doxyl stearic acid spin probe in ethanol to 50 μL of serum from each patient to create 3 different aliquots that differed in concentration of spin probe and ethanol, then incubated the aliquots for 10 min at 37 ̊C with continuous shaking. We measured the ESR spectra of each aliquot in triplicate and used proprietary software (MedInnovation GmbH) to evaluate the ESR spectrum for differences between cancer patients and the other groups. Results: The diagnostic sensitivity and specificity of this test were 87.4% and 95.7%, respectively, for differentiating healthy individuals from cancer patients and 87.4%, and 85.7% for differentiating cancer patients from chronic disease patients. Serial evaluation of albumin conformation changes in several patients followed during the course of their disease showed excellent agreement between the magnitude of abnormality in the ESR spectrum of albumin and clinical and pathologic estimates of disease severity. Conclusions: ESR spectroscopy of serum albumin is a sensitive and noninvasive technique that clearly demonstrates diagnostic utility in patients with cancer. This test also enables monitoring of the disease course through .use of serial measurements.

Original languageEnglish (US)
Pages (from-to)2129-2134
Number of pages6
JournalClinical Chemistry
Volume52
Issue number11
DOIs
StatePublished - Nov 2006

Fingerprint

Electron spin resonance spectroscopy
Electron Spin Resonance Spectroscopy
Serum Albumin
Paramagnetic resonance
Monitoring
Albumins
Neoplasms
Ethanol
Pulmonary diseases
Medical problems
Chronic Disease
Conformations
Spectrometers
Tumors
Blood
Cells
Gastrointestinal Diseases
Hematologic Neoplasms
Lung Diseases
Healthy Volunteers

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Electron spin resonance spectroscopy of serum albumin : A novel new test for cancer diagnosis and monitoring. / Kazmierczak, Steven (Steve); Gurachevsky, Andrey; Matthes, Gert; Muravsky, Vladimir.

In: Clinical Chemistry, Vol. 52, No. 11, 11.2006, p. 2129-2134.

Research output: Contribution to journalArticle

Kazmierczak, Steven (Steve) ; Gurachevsky, Andrey ; Matthes, Gert ; Muravsky, Vladimir. / Electron spin resonance spectroscopy of serum albumin : A novel new test for cancer diagnosis and monitoring. In: Clinical Chemistry. 2006 ; Vol. 52, No. 11. pp. 2129-2134.
@article{7dd12afbdc74459da60fc5d3a3193182,
title = "Electron spin resonance spectroscopy of serum albumin: A novel new test for cancer diagnosis and monitoring",
abstract = "Background: Proteins released by tumor cells can bind to serum albumin, leading to structural and functional modifications. We used electron spin resonance (ESR) spectroscopy to measure these changes in serum albumin and evaluate their utility for the diagnosis and monitoring of cancer. Methods: We used an ESR spectrometer and 16-doxyl stearic acid as spin probe to measure conformational changes in albumin in blood samples from a population of healthy donors and volunteers (n = 349), patients with a wide variety of hematologic and nonhematologic malignancy (n = 135), and patients with chronic diseases such as gastrointestinal and pulmonary disease, diabetes, and cirrhosis (n = 91). We added differing amounts of 16-doxyl stearic acid spin probe in ethanol to 50 μL of serum from each patient to create 3 different aliquots that differed in concentration of spin probe and ethanol, then incubated the aliquots for 10 min at 37 ̊C with continuous shaking. We measured the ESR spectra of each aliquot in triplicate and used proprietary software (MedInnovation GmbH) to evaluate the ESR spectrum for differences between cancer patients and the other groups. Results: The diagnostic sensitivity and specificity of this test were 87.4{\%} and 95.7{\%}, respectively, for differentiating healthy individuals from cancer patients and 87.4{\%}, and 85.7{\%} for differentiating cancer patients from chronic disease patients. Serial evaluation of albumin conformation changes in several patients followed during the course of their disease showed excellent agreement between the magnitude of abnormality in the ESR spectrum of albumin and clinical and pathologic estimates of disease severity. Conclusions: ESR spectroscopy of serum albumin is a sensitive and noninvasive technique that clearly demonstrates diagnostic utility in patients with cancer. This test also enables monitoring of the disease course through .use of serial measurements.",
author = "Kazmierczak, {Steven (Steve)} and Andrey Gurachevsky and Gert Matthes and Vladimir Muravsky",
year = "2006",
month = "11",
doi = "10.1373/clinchem.2006.073148",
language = "English (US)",
volume = "52",
pages = "2129--2134",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "11",

}

TY - JOUR

T1 - Electron spin resonance spectroscopy of serum albumin

T2 - A novel new test for cancer diagnosis and monitoring

AU - Kazmierczak, Steven (Steve)

AU - Gurachevsky, Andrey

AU - Matthes, Gert

AU - Muravsky, Vladimir

PY - 2006/11

Y1 - 2006/11

N2 - Background: Proteins released by tumor cells can bind to serum albumin, leading to structural and functional modifications. We used electron spin resonance (ESR) spectroscopy to measure these changes in serum albumin and evaluate their utility for the diagnosis and monitoring of cancer. Methods: We used an ESR spectrometer and 16-doxyl stearic acid as spin probe to measure conformational changes in albumin in blood samples from a population of healthy donors and volunteers (n = 349), patients with a wide variety of hematologic and nonhematologic malignancy (n = 135), and patients with chronic diseases such as gastrointestinal and pulmonary disease, diabetes, and cirrhosis (n = 91). We added differing amounts of 16-doxyl stearic acid spin probe in ethanol to 50 μL of serum from each patient to create 3 different aliquots that differed in concentration of spin probe and ethanol, then incubated the aliquots for 10 min at 37 ̊C with continuous shaking. We measured the ESR spectra of each aliquot in triplicate and used proprietary software (MedInnovation GmbH) to evaluate the ESR spectrum for differences between cancer patients and the other groups. Results: The diagnostic sensitivity and specificity of this test were 87.4% and 95.7%, respectively, for differentiating healthy individuals from cancer patients and 87.4%, and 85.7% for differentiating cancer patients from chronic disease patients. Serial evaluation of albumin conformation changes in several patients followed during the course of their disease showed excellent agreement between the magnitude of abnormality in the ESR spectrum of albumin and clinical and pathologic estimates of disease severity. Conclusions: ESR spectroscopy of serum albumin is a sensitive and noninvasive technique that clearly demonstrates diagnostic utility in patients with cancer. This test also enables monitoring of the disease course through .use of serial measurements.

AB - Background: Proteins released by tumor cells can bind to serum albumin, leading to structural and functional modifications. We used electron spin resonance (ESR) spectroscopy to measure these changes in serum albumin and evaluate their utility for the diagnosis and monitoring of cancer. Methods: We used an ESR spectrometer and 16-doxyl stearic acid as spin probe to measure conformational changes in albumin in blood samples from a population of healthy donors and volunteers (n = 349), patients with a wide variety of hematologic and nonhematologic malignancy (n = 135), and patients with chronic diseases such as gastrointestinal and pulmonary disease, diabetes, and cirrhosis (n = 91). We added differing amounts of 16-doxyl stearic acid spin probe in ethanol to 50 μL of serum from each patient to create 3 different aliquots that differed in concentration of spin probe and ethanol, then incubated the aliquots for 10 min at 37 ̊C with continuous shaking. We measured the ESR spectra of each aliquot in triplicate and used proprietary software (MedInnovation GmbH) to evaluate the ESR spectrum for differences between cancer patients and the other groups. Results: The diagnostic sensitivity and specificity of this test were 87.4% and 95.7%, respectively, for differentiating healthy individuals from cancer patients and 87.4%, and 85.7% for differentiating cancer patients from chronic disease patients. Serial evaluation of albumin conformation changes in several patients followed during the course of their disease showed excellent agreement between the magnitude of abnormality in the ESR spectrum of albumin and clinical and pathologic estimates of disease severity. Conclusions: ESR spectroscopy of serum albumin is a sensitive and noninvasive technique that clearly demonstrates diagnostic utility in patients with cancer. This test also enables monitoring of the disease course through .use of serial measurements.

UR - http://www.scopus.com/inward/record.url?scp=33750455142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750455142&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2006.073148

DO - 10.1373/clinchem.2006.073148

M3 - Article

C2 - 16990414

AN - SCOPUS:33750455142

VL - 52

SP - 2129

EP - 2134

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 11

ER -